Table 1.
Group A (n=6) | Group B (n=25) | Group C (n=20) | P value | |
---|---|---|---|---|
Median age, years (range) | 55.3 (44-66) | 57.0 (34-72) | 52.9 (33-72) | 0.41 |
Age≥65years (n,%) | 1 (16.7%) | 6 (24%) | 3 (15%) | 0.74 |
Male gender (n,%) | 5 (83.3%) | 13 (52%) | 11 (55%) | 0.37 |
Stage III-IV at diagnosis (n,%) | 6 (100%) | 20 (80%) | 17 (85%) | 0.48 |
Median LDH at diagnosis, U/L (range) | 240.1 (167-361) | 299.9 (98-803) | 302.3 (129-917) | 0.74 |
Bone marrow involvement at diagnosis (n,%) | 5 (83.3%) | 1 (4%) | 3 (15%) | <0.001 |
Extra nodal or CNS involvement at diagnosis (n,%) | 2 (33.3%) | 12 (48%) | 7 (35%) | 0.62 |
Median number of lines prior to CAR-T (range) | 3 (2-5) | 3.3 (2-7) | 3.1 (2-6) | 0.59 |
Transformed DLBCL | 1 (16.7%) | 3 (12%) | 1 (5%) | 0.61 |
Previous ASCT | 2 (33.3%) | 5 (20%) | 3 (14.3%) | 0.61 |
Previous use of CD20 antibody (n,%) | 5 (83.3%) | 25 (100%) | 18 (90%) | 0.18 |
Primary refractory after first line of therapy (n,%) | 3 (50%) | 9 (36%) | 4 (20%) | 0.30 |
LDH for lactate dehydrogenase, CNS for central nervous system, CAR-T for chimeric antigen receptor T cell therapy, DLBCL for diffuse large B-cell lymphoma, ASCT for autologous stem cell transplantation